e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Therapeutic approaches in inflammatory lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts
Christopher Lambers (Vienna, Austria), Christopher Lambers, Zhoa Feng, Peter Jaksch, Walter Klepetko, Michael Roth
Source:
International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Session:
Therapeutic approaches in inflammatory lung disease
Session type:
Thematic Poster Session
Number:
3893
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Christopher Lambers (Vienna, Austria), Christopher Lambers, Zhoa Feng, Peter Jaksch, Walter Klepetko, Michael Roth. Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts. Eur Respir J 2015; 46: Suppl. 59, 3893
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Role of endothelin in lung fibrosis
Source: Eur Respir Rev 2008; 17: 145-150
Year: 2008
Extracellular matrix profile of lung in idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Year: 2013
NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts
Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung
Year: 2009
Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Nintedanib inhibits contractile activity of lung myofibroblasts in a cellular model of scleroderma associated pulmonary fibrosis
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept